WebMay 3, 2024 · The company is also developing a pipeline of lncRNA-targeting candidates for the tissue-specific treatment of fibrotic diseases in other tissues, including lungs, kidney, liver, and the micro-environment of solid tumor cancers. Haya Therapeutics was founded in 2024 and is based in Lausanne, Switzerland. WebAug 10, 2024 · LAUSANNE, Switzerland--(BUSINESS WIRE)-- HAYA Therapeutics, SA, a company developing precision medicines that target tissue and cell-specific long non-coding RNAs (lncRNAs), today announced the formation and members of its Scientific Advisory Board (SAB).The group of world-renowned leaders and pioneers are recognized for their …
HAYA Therapeutics SA - startup.ch
WebFeb 15, 2024 · This is why I co-founded HAYA Therapeutics. HAYA’s approach targets these important information processing features within our source code, long non-coding RNAs (lncRNAs), for the safer and more ... WebFeb 16, 2024 · LAUSANNE, Switzerland & SAN DIEGO, February 16, 2024 -- ( BUSINESS WIRE )-- HAYA Therapeutics, SA, a company developing RNA-guided programmable … forgery iron doors
Haya Therapeutics Closes CHF 18M Funding - FinSMEs
WebFeb 9, 2024 · LAUSANNE, Switzerland & SAN DIEGO, February 09, 2024--Haya established a new laboratory space at JLABS @ San Diego, part of Johnson & Johnson Innovation’s global network of life science incubators. WebHaYa Therapeutics SUPERLAB Serine Building Route de la Corniche 6 1066 Epalinges. Keywords. Cardiology; Latest news related to HaYa Therapeutics. 08.09 2024 ... Switzerland Visiting information. Contact. … WebMay 3, 2024 · LAUSANNE, Switzerland & SAN DIEGO--(BUSINESS WIRE)-- HAYA Therapeutics, SA, a company developing precision medicines that target tissue and cell … difference between a territory and a state